SCCM Resource Library-The Role of Platform Trials

Video Transcription

Video Summary

The speaker is a project officer from the Influenza and Emerging Infectious Disease Division focusing on therapeutics. They discuss the organization's efforts in developing medical countermeasures for public health emergencies, like influenza and COVID-19. Their focus is on drug repurposing and effective trial designs for conditions like ARDS. They emphasize the need for biomarkers and comprehensive trials to improve treatment outcomes. A recent phase two ARDS trial involves 600 patients to develop host-directed therapies, collecting extensive data for disease and treatment insights. Additionally, they encourage industry collaboration for advanced ARDS treatments.

Asset Caption

90-Minute Session | Clinical Evidence for Host-Directed Therapeutics

Meta Tag

Content Type Presentation

Membership Level Professional

Membership Level Select

Year 2024

Keywords

therapeutics

medical countermeasures

ARDS

biomarkers

industry collaboration

	Society of Critical Care Medicine 500 Midway Drive Mount Prospect, IL 60056 USA Phone: +1 847 827-6888 Fax: +1 847 439-7226 Email: support@sccm.org	Contact Us About SCCM Newsroom Advertising & Sponsorship DONATE	MySCCM LearnICU Patients & Families Surviving Sepsis Campaign Critical Care Societies Collaborative	GET OUR NEWSLETTER
© Society of Critical Care Medicine. All rights reserved. \| Privacy Statement \| Terms & Conditions The Society of Critical Care Medicine, SCCM, and Critical Care Congress are registered trademarks of the Society of Critical Care Medicine.